Rigel Pharmaceuticals Q2 revenue beats estimates

Rigel Pharmaceuticals

05/08/2025 21:27

Overview

Rigel Q2 2025 revenue of $101.7 mln beats analyst expectations, per LSEG data

Company reports Q2 net income of $59.6 mln, reversing a loss from last year

Net product sales grew 76% yr/yr, driven by TAVALISSE and GAVRETO

Outlook

Rigel updates 2025 revenue guidance to $270-$280 mln

Company expects net product sales of $210-$220 mln in 2025

Rigel forecasts $60 mln in contract revenues from collaborations

Company anticipates positive net income for full-year 2025

Result Drivers

NET PRODUCT SALES - Rigel's net product sales increased by 76% year-over-year, driven by TAVALISSE and GAVRETO

NON-CASH REVENUE - Recognized $40 mln in non-cash revenue from agreement with Eli Lilly, contributing to contract revenues

INTERNATIONAL EXPANSION - Launch of TAVALISSE in South Korea by partner Kissei contributed to sales growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$101.70 mln
$88.90 mln (3 Analysts)
Q2 EPS
$3.28
Q2 Net Income
$59.6 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Rigel Pharmaceuticals Inc is $23.50, about 3.5% above its August 4 closing price of $22.67

The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release: ID:nPn9cRZ7Ka

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)